Mixed Results for Inhaled Insulin for Type 2 Diabetes

Preprandial inhaled insulin can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin, according to a new review of the body of published research. People who use insulin to manage their type 2 diabetes typically have to take extra insulin at mealtimes to regulate the glucose response to food. They can use short-acting injected insulin or inhaled insulin.

The review examined several clinical issues surrounding the use of inhaled insulin by patients with type 2 diabetes. It looked at how inhaled insulin compares to injected insulin as a mealtime insulin supplement for patients who are already using injected insulin daily.

The report also compared use of inhaled insulin by type 2 diabetes patients who had not previously taken insulin in any form. Inhaled insulin was compared to the effectiveness of oral antidiabetic drugs used alone and to antidiabetic drugs used with inhaled insulin.

In patients with type 2 diabetes, inhaled insulin worked as well as short-acting injected insulin to control blood glucose over 3 months, according to the review. However, inhaled insulin users had more trouble controlling low blood glucose — hypoglycemia –a common complication of diabetes medication.

Among patients who had not previously taken insulin in any form, inhaled insulin alone was more effective than oral diabetes medication at controlling blood glucose levels at the three-month follow-up. When patients took oral medication plus inhaled insulin, higher rates of hypoglycemia occurred.

The Windows on Medical Technology report is published by ECRI Institute, an independent nonprofit health services research agency that researches the best approaches to improving patient care. Jonathan Treadwell, PhD, senior research analyst at ECRI Institute, led a team of investigators who analyzed eight studies encompassing 1,881 patients with type 2 diabetes to make the comparisons between inhaled insulin, injected insulin, and oral medication regimens.

Despite some positive findings, the authors write, "the evidence regarding inhaled insulin for patients with type 2 diabetes is still insufficient to answer many key clinical questions" such as patient satisfaction, inhaled insulin’s effect on other complications of diabetes, on weight gain, and very importantly, the long-term effects on lung function.

"One detail to note about inhaled insulin — the dosing is not as precise as with injections because specific increments in doses are not as precise," Treadwell said.

Its convenience makes inhaled insulin an attractive option, although it may not be the right medication for every diabetes patient who needs insulin.

According to the American Diabetes Association it is unclear if delivering insulin through the lungs could result in long-term respiratory problems.

"This is the reason for resistance by doctors and patients to inhaled insulin — long-term lung damage," Treadwell said. "It’s a valid concern since it is suspected that people with diabetes already have lung problems — the concern is that this form of administration would exacerbate these problems."

"It’s too early to say if inhaled insulin could be used to the extent that injected insulin is — our review only covered 6 month follow-up because that’s the only data currently available. The question is: Could it provide long-term glucose control without damaging effects?" Treadwell said.

Treadwell J, et al. Inhaled insulin for the treatment of type 2 diabetes. Windows on Medical Technology July 2007 Issue No. 146.

===========================

Advertisement
Do you have patients in pain? Over 5,000 Anodyne Therapy Care Providers in 35 countries worldwide are helping thousands of patients per month with painful, circulatory problems get relief. To learn how you can help your patients get back to life, click here.